Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 2
2002 11
2003 7
2004 18
2005 36
2006 35
2007 31
2008 50
2009 65
2010 84
2011 91
2012 110
2013 115
2014 120
2015 170
2016 183
2017 210
2018 171
2019 194
2020 212
2021 199
2022 263
2023 68
Text availability
Article attribute
Article type
Publication date

Search Results

2,173 results
Results by year
Filters applied: . Clear all
Page 1
Targeting OCT3 attenuates doxorubicin-induced cardiac injury.
Huang KM, Zavorka Thomas M, Magdy T, Eisenmann ED, Uddin ME, DiGiacomo DF, Pan A, Keiser M, Otter M, Xia SH, Li Y, Jin Y, Fu Q, Gibson AA, Bonilla IM, Carnes CA, Corps KN, Coppola V, Smith SA, Addison D, Nies AT, Bundschuh R, Chen T, Lustberg MB, Wang J, Oswald S, Campbell MJ, Yan PS, Baker SD, Hu S, Burridge PW, Sparreboom A. Huang KM, et al. Among authors: fu q. Proc Natl Acad Sci U S A. 2021 Feb 2;118(5):e2020168118. doi: 10.1073/pnas.2020168118. Proc Natl Acad Sci U S A. 2021. PMID: 33495337 Free PMC article.
Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease.
Zhang Y, Jiang L, Wang J, Wang T, Chien C, Huang W, Fu X, Xiao Y, Fu Q, Wang S, Zhao J. Zhang Y, et al. Among authors: fu q. Cardiovasc Diabetol. 2022 Nov 5;21(1):232. doi: 10.1186/s12933-022-01676-5. Cardiovasc Diabetol. 2022. PMID: 36335326 Free PMC article.
Inflammatory microenvironment-targeted nanotherapies.
Zhang G, Ma L, Bai L, Li M, Guo T, Tian B, He Z, Fu Q. Zhang G, et al. Among authors: fu q. J Control Release. 2021 Jun 10;334:114-126. doi: 10.1016/j.jconrel.2021.04.018. Epub 2021 Apr 20. J Control Release. 2021. PMID: 33887284 Review.
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.
Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA. Stephens DM, et al. Among authors: fu q. Clin Cancer Res. 2022 Aug 2;28(15):3242-3247. doi: 10.1158/1078-0432.CCR-21-3867. Clin Cancer Res. 2022. PMID: 35608822 Free PMC article. Clinical Trial.
2,173 results